KalVista Pharmaceuticals

News

Lilly's appeal unlocks EU approval of Alzheimer's drug

Eli Lilly's appeal of a decision by the EMA's human medicines committee not to approve its Alzheimer's disease therapy Kisunla has paid off.

News

KalVista bags FDA approval for delayed oral HAE drug

KalVista has brought the first oral, on-demand treatment for hereditary angioedema attacks to the US market.

News

KalVista files first oral on-demand HAE drug with FDA

KalVista Pharma has filed its first marketing application to the US FDA, seeking approval for its oral plasma kallikrein inhibitor sebetralstat as an oral treatment for hereditary angioedem

R&D

This week in clinical trials: 12th to 16th February 2024

In this instalment of our week-by-week clinical trials round-up, we look at life sciences research and development announced during the week of 12th to 16th February, from early-stage onwar

Lilly's appeal unlocks EU approval of Alzheimer's drug

KalVista bags FDA approval for delayed oral HAE drug

KalVista files first oral on-demand HAE drug with FDA

This week in clinical trials: 12th to 16th February 2024

FDA approves higher Wegovy dose via 4th priority voucher

Using AI-driven synthetic personas to take your insights fur...

KalVista Pharmaceuticals

Editor's Picks